Harbour Mice^® - New Generation Of Fully Human Monoclonal Antibody Platforms And Highly Effective Engine For Generating Novel Therapeutics  

Harbour BioMed has particular Harbour Mice^® antibody technology platforms. The proprietary Harbour Mice^®  generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Integrated with the single B cell cloning platform, it is highly unique and efficient for development of next generation therapeutic antibodies. The Harbour antibody platform will contribute to the discovery and development of novel efficient receptors (such as CAR) for NK cell therapy.